Hematologia Geral
Estudo de coorte | Sustentabilidade de uma intervenção de apoio a decisão clínica voltada para estimular o cuidado ambulatorial de pacientes selecionados com embolia pulmonar aguda.
18 Mai, 2022 | 16:45hConteúdo relacionado: Outpatient versus inpatient treatment for acute pulmonary embolism – Cochrane Library
Comentário no Twitter
This multicenter cohort study of ED patients with acute pulmonary embolism found the initial increase in outpatient management from a physician champion-led, EHR-embedded clinical decision support intervention was sustained 4 years later. https://t.co/UPf8pAOTry
— JAMA Network Open (@JAMANetworkOpen) May 16, 2022
M-A | Anticoagulantes orais diretos não são tão efetivos quanto os antagonistas de vitamina K em pacientes com síndrome antifosfolípide.
16 Mai, 2022 | 16:13hRevisão | Linfo-histiocitose hemofagocítica em pacientes com HIV.
12 Mai, 2022 | 14:53hA Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases
Ponto/Contraponto | Heparina terapêutica deveria ser administrada para pacientes críticos internados com COVID-19?
4 Mai, 2022 | 14:00hCONTRPONTO: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST
Ver também: Rebuttal From Dr Tritschler et al – CHEST
Conteúdos relacionados:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Estimativas nacionais, regionais e globais de anemia conforme a gravidade em mulheres e crianças de 2000 a 2019.
21 Abr, 2022 | 12:09hComentário convidado: Sustainable Development Goals for anaemia: 20 years later, where are we now? – The Lancet Global Health
Estudo clínico fases 1-2 | Rilzabrutinibe, um inibidor BTK oral, na trombocitopenia imune.
21 Abr, 2022 | 11:21hRilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial – Massachusetts General Hospital
Comentário no Twitter
Rilzabrutinib had rapid and durable clinical activity in adults with immune thrombocytopenia, with low-level toxic effects. https://t.co/boWT4LpQkk pic.twitter.com/ZpNXHYL2Gv
— NEJM (@NEJM) April 18, 2022
Estudo randomizado | Mitapivate vs. placebo para deficiência de piruvatoquinase.
19 Abr, 2022 | 12:31hMitapivat versus Placebo for Pyruvate Kinase Deficiency – New England Journal of Medicine
Estudo de coorte | Tipo sanguíneo não O está associado a risco aumentado de tromboembolismo venoso em pacientes com câncer.
18 Abr, 2022 | 15:19hABO blood group type and risk of venous thromboembolism in patients with cancer – Blood Advances (link para o resumo – $ para o texto completo)
Revisão | Manifestações cutâneas da gamopatia monoclonal.
18 Abr, 2022 | 15:13hCutaneous manifestations of monoclonal gammopathy – Blood Cancer Journal
M-A | Padrões de trombose e desfecho clínico da trombocitopenia trombótica imune induzida por vacina contra COVID-19.
11 Abr, 2022 | 12:58hConteúdos relacionados:
Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.
Review: Vaccine-induced immune thrombotic thrombocytopenia.
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.
Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)